Therapeutic vaccination using patient-derived immune cells for lung cancer treatment
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
This study is testing a new type of vaccine for people with non-small cell lung cancer that uses their own immune cells to help their body fight the cancer better, focusing on specific markers in their tumors to create a personalized treatment that could lead to improved results.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10893578 on NIH RePORTER |
What this research studies
This research investigates a novel vaccination approach for patients with non-small cell lung cancer (NSCLC) that focuses on using their own immune cells, specifically dendritic cells, to enhance the body's immune response against cancer. The study aims to identify specific tumor neoantigens that can trigger a stronger immune reaction, particularly in patients with certain genetic markers. By customizing the vaccine to target these neoepitopes, the goal is to improve the effectiveness of immunotherapy and provide a more personalized treatment option for patients. Participants will receive a vaccination designed to activate their immune system against their cancer cells, potentially leading to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have specific genetic markers related to HLA-B binding pockets.
Not a fit: Patients with lung cancer who do not have the targeted genetic markers or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for lung cancer patients, improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with dendritic cell-based vaccines in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Garon, Edward B — University of California Los Angeles
- Study coordinator: Garon, Edward B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.